These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 10888616)

  • 21. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever.
    Cashman KA; Wilkinson ER; Shaia CI; Facemire PR; Bell TM; Bearss JJ; Shamblin JD; Wollen SE; Broderick KE; Sardesai NY; Schmaljohn CS
    Hum Vaccin Immunother; 2017 Dec; 13(12):2902-2911. PubMed ID: 29045192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
    Bredenbeek PJ; Molenkamp R; Spaan WJ; Deubel V; Marianneau P; Salvato MS; Moshkoff D; Zapata J; Tikhonov I; Patterson J; Carrion R; Ticer A; Brasky K; Lukashevich IS
    Virology; 2006 Feb; 345(2):299-304. PubMed ID: 16412488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
    Cai Y; Iwasaki M; Motooka D; Liu DX; Yu S; Cooper K; Hart R; Adams R; Burdette T; Postnikova EN; Kurtz J; St Claire M; Ye C; Kuhn JH; Martínez-Sobrido L; de la Torre JC
    mBio; 2020 Mar; 11(2):. PubMed ID: 32209677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins.
    Wang M; Jokinen J; Tretyakova I; Pushko P; Lukashevich IS
    Vaccine; 2018 Jan; 36(5):683-690. PubMed ID: 29287681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.
    Abreu-Mota T; Hagen KR; Cooper K; Jahrling PB; Tan G; Wirblich C; Johnson RF; Schnell MJ
    Nat Commun; 2018 Oct; 9(1):4223. PubMed ID: 30310067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid protection induced by a single-shot Lassa vaccine in male cynomolgus monkeys.
    Mateo M; Reynard S; Pietrosemoli N; Perthame E; Journeaux A; Noy K; Germain C; Carnec X; Picard C; Borges-Cardoso V; Hortion J; Lopez-Maestre H; Regnard P; Fellmann L; Vallve A; Barron S; Jourjon O; Lacroix O; Duthey A; Dirheimer M; Daniau M; Legras-Lachuer C; Carbonnelle C; Raoul H; Tangy F; Baize S
    Nat Commun; 2023 Mar; 14(1):1352. PubMed ID: 36906645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection.
    Auperin DD; Esposito JJ; Lange JV; Bauer SP; Knight J; Sasso DR; McCormick JB
    Virus Res; 1988 Feb; 9(2-3):233-48. PubMed ID: 3354260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathogenesis of Lassa fever.
    Yun NE; Walker DH
    Viruses; 2012 Oct; 4(10):2031-48. PubMed ID: 23202452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.
    Leblanc P; Moise L; Luza C; Chantaralawan K; Lezeau L; Yuan J; Field M; Richer D; Boyle C; Martin WD; Fishman JB; Berg EA; Baker D; Zeigler B; Mais DE; Taylor W; Coleman R; Warren HS; Gelfand JA; De Groot AS; Brauns T; Poznansky MC
    Hum Vaccin Immunother; 2014; 10(10):3022-38. PubMed ID: 25483693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.
    Mire CE; Cross RW; Geisbert JB; Borisevich V; Agans KN; Deer DJ; Heinrich ML; Rowland MM; Goba A; Momoh M; Boisen ML; Grant DS; Fullah M; Khan SH; Fenton KA; Robinson JE; Branco LM; Garry RF; Geisbert TW
    Nat Med; 2017 Oct; 23(10):1146-1149. PubMed ID: 28869611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lassa fever: implications of T-cell immunity for vaccine development.
    ter Meulen J
    J Biotechnol; 1999 Aug; 73(2-3):207-12. PubMed ID: 10486929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model.
    Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Klena JD; Nichol ST; Albariño CG; Spiropoulou CF
    J Infect Dis; 2018 May; 217(12):1957-1966. PubMed ID: 29800368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.
    Zapata JC; Goicochea M; Nadai Y; Eyzaguirre LM; Carr JK; Tallon LJ; Sadzewicz L; Myers G; Fraser CM; Su Q; Djavani M; Lukashevich IS; Salvato MS
    J Virol; 2014 Mar; 88(6):3058-66. PubMed ID: 24335292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein.
    ter Meulen J; Badusche M; Kuhnt K; Doetze A; Satoguina J; Marti T; Loeliger C; Koulemou K; Koivogui L; Schmitz H; Fleischer B; Hoerauf A
    J Virol; 2000 Mar; 74(5):2186-92. PubMed ID: 10666248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advanced vaccine candidates for Lassa fever.
    Lukashevich IS
    Viruses; 2012 Oct; 4(11):2514-57. PubMed ID: 23202493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The search for animal models for Lassa fever vaccine development.
    Lukashevich IS
    Expert Rev Vaccines; 2013 Jan; 12(1):71-86. PubMed ID: 23256740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot.
    Mateo M; Reynard S; Carnec X; Journeaux A; Baillet N; Schaeffer J; Picard C; Legras-Lachuer C; Allan R; Perthame E; Hillion KH; Pietrosemoli N; Dillies MA; Barrot L; Vallve A; Barron S; Fellmann L; Gaillard JC; Armengaud J; Carbonnelle C; Raoul H; Tangy F; Baize S
    Sci Transl Med; 2019 Oct; 11(512):. PubMed ID: 31578242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccine platforms for the prevention of Lassa fever.
    Purushotham J; Lambe T; Gilbert SC
    Immunol Lett; 2019 Nov; 215():1-11. PubMed ID: 31026485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Common CD8
    Sakabe S; Hartnett JN; Ngo N; Goba A; Momoh M; Sandi JD; Kanneh L; Cubitt B; Garcia SD; Ware BC; Kotliar D; Robles-Sikisaka R; Gangavarapu K; Branco LM; Eromon P; Odia I; Ogbaini-Emovon E; Folarin O; Okogbenin S; Okokhere PO; Happi C; Sabeti PC; Andersen KG; Garry RF; de la Torre JC; Grant DS; Schieffelin JS; Oldstone MBA; Sullivan BM
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32269122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model.
    Kennedy EM; Dowall SD; Salguero FJ; Yeates P; Aram M; Hewson R
    Vaccine; 2019 Aug; 37(36):5404-5413. PubMed ID: 31331770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.